GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Forward Dividend Yield %

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Forward Dividend Yield % : 0.00% (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Forward Dividend Yield %?

As of today (2024-05-14), the Forward Annual Dividend Yield of Clarus Therapeutics Holdings is 0.00%.

As of today (2024-05-14), the Trailing Annual Dividend Yield of Clarus Therapeutics Holdings is 0.00%.

CRXTQ's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.85
* Ranked among companies with meaningful Forward Dividend Yield % only.

Clarus Therapeutics Holdings's Dividends per Share for the three months ended in Jun. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Clarus Therapeutics Holdings's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarus Therapeutics Holdings's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Forward Dividend Yield % falls into.



Clarus Therapeutics Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Clarus Therapeutics Holdings  (OTCPK:CRXTQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Clarus Therapeutics Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus